Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REGENXBIO Inc. Director's Dealing 2017

Jan 6, 2017

32827_dirs_2017-01-06_c30bb7a5-ce6d-4899-8ec9-46b811399de0.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENXBIO Inc. (RGNX)
CIK: 0001590877
Period of Report: 2017-01-04

Reporting Person: Christmas Patrick J. (SVP, General Counsel)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-01-04 Stock Option (Right to Buy) $19.50 A 11100 Acquired 2027-01-03 Common Stock (11100) Direct

Footnotes

F1: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 1/4/2018 while the optionee provides continuous service to the Issuer.